RhumbLine Advisers
CSTL icon

RhumbLine Advisers’s Castle Biosciences CSTL Stock Holding History

RhumbLine Advisers’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$930K Buy
39,010
+632
+2% +$14.1K ﹤0.01% 2357
2026
Q1 		$942K Sell
38,378
-90
-0.2% -$2.95K ﹤0.01% 2222
2025
Q4 		$1.5M Sell
38,468
-5,290
-12% -$171K ﹤0.01% 2030
2025
Q3 		$996K Sell
43,758
-1,639
-4% -$33.3K ﹤0.01% 2241
2025
Q2 		$927K Buy
45,397
+6,211
+16% +$115K ﹤0.01% 2287
2025
Q1 		$784K Sell
39,186
-706
-2% -$17.5K ﹤0.01% 2289
2024
Q4 		$1.06M Sell
39,892
-1,009
-2% -$30.7K ﹤0.01% 2224
2024
Q3 		$1.17M Sell
40,901
-995
-2% -$25.3K ﹤0.01% 2187
2024
Q2 		$912K Buy
41,896
+2,988
+8% +$66.6K ﹤0.01% 2302
2024
Q1 		$862K Buy
38,908
+1,000
+3% +$21.8K ﹤0.01% 2330
2023
Q4 		$818K Buy
37,908
+60
+0.2% +$1.06K ﹤0.01% 2376
2023
Q3 		$639K Buy
37,848
+539
+1% +$9.43K ﹤0.01% 2460
2023
Q2 		$512K Sell
37,309
-1,986
-5% -$40.2K ﹤0.01% 2671
2023
Q1 		$893K Buy
39,295
+1,383
+4% +$33.8K ﹤0.01% 2174
2022
Q4 		$892K Buy
37,912
+393
+1% +$9.11K ﹤0.01% 2194
2022
Q3 		$978K Buy
37,519
+3,239
+9% +$90.8K ﹤0.01% 2141
2022
Q2 		$752K Buy
34,280
+12,344
+56% +$287K ﹤0.01% 2281
2022
Q1 		$984K Buy
21,936
+1,038
+5% +$42.9K ﹤0.01% 2138
2021
Q4 		$896K Sell
20,898
-357
-2% -$18.7K ﹤0.01% 2254
2021
Q3 		$1.41M Buy
21,255
+832
+4% +$58.5K ﹤0.01% 2072
2021
Q2 		$1.5M Buy
20,423
+5,913
+41% +$391K ﹤0.01% 2079
2021
Q1 		$993K Buy
14,510
+1,007
+7% +$75.7K ﹤0.01% 2191
2020
Q4 		$907K Buy
13,503
+1,027
+8% +$55.7K ﹤0.01% 2178
2020
Q3 		$642K Sell
12,476
-288
-2% -$12.8K ﹤0.01% 2173
2020
Q2 		$481K Buy
12,764
+3,520
+38% +$120K ﹤0.01% 2361
2020
Q1 		$276K Buy
+9,244
New +$279K ﹤0.01% 2446

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

RhumbLine Advisers's CSTL Position: Q2 2026 in Review

RhumbLine Advisers increased its Castle Biosciences (CSTL) stake by 1.6% in Q2 2026, buying an estimated $14.1K and bringing the position to 39,010 shares worth $930K. The position accounts for ﹤0.01% of the portfolio, ranked #2357.

RhumbLine Advisers first reported a position in CSTL in Q1 2020 and has held it in 26 quarters since. The position peaked at $1.5M in Q2 2021. 177 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • RhumbLine Advisers held 39,010 shares of Castle Biosciences worth $930K as of Q2 2026.
  • RhumbLine Advisers bought 632 Castle Biosciences shares in Q2 2026, an estimated $14.1K.
  • Castle Biosciences made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2357 holding.
  • RhumbLine Advisers first reported a position in Castle Biosciences in Q1 2020 and has held it in 26 quarters since.
  • RhumbLine Advisers's Castle Biosciences position peaked at $1.5M in Q2 2021.
  • 177 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.